Neuroendocrine Tumor Imaging With ⁶⁸Ga-DOTA-NOC: Physiologic and Benign Variants

Abstract

Previously unreported benign sites of 68Ga-DOTA-NOC uptake were found in the majority of studies, suggesting the presence of somatostatin receptors in physiologic variants or processes with no evidence of tumor. Knowledge of increased tracer uptake in non-NET-related sites is important for accurate interpretation and for avoiding potential pitfalls of 68Ga-DOTA-NOC PET/CT.

Breast Uptake of Ga-68 DOTA-TATE in a Nursing Woman with Net Diagnosis

“…They found 29 sites of diffuse 68Ga-DOTA-NOC uptake in the breasts in 14 of the 96 female patients with SUVmax range of 0.8-2.7. Low and variable expression of SSTR 2 has been reported in breast tissue unaffected by disease (8). In our case, we demonstrated Ga-68 DOTA-TATE uptake in the bilateral breasts in a nursing patient newly diagnosed with NET.…”

Improving PET Quantification of Small Animal [68Ga]DOTA-Labeled PET/CT Studies by Using a CT-Based Positron Range Correction

“…[ 68 Ga]DOTA-labeled somatostatin analogues bind specifically to somatostatin receptors (SSTRs) and are commonly used for imaging and treatment planning of neuroendocrine tumors (NETs) [3][4][5][6][7][8]. Moreover, [ 68 Ga]DOTA-labeled somatostatin analogues have been reported to show higher sensitivity for the detection of NETs and other somatostatin-receptor expressing tumors than the most widely used radiotracer, 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG), which is used to measure glucose metabolism [9][10][11].…”

Non‐invasive methods for the assessment of brown adipose tissue in humans

“…68 Ga-DOTA-NOC (t 1/2 = 68 min) is an octreotide analogue that binds somatostatin receptors. In a retrospective review of diagnostic 68 Ga-DOTA-NOC-PET scans, Kagna et al reported increased 68 Ga-DOTA-NOC uptake in fat depots linked to BAT only in 1% of patients (Kagna et al 2014). Considering the very low prevalence of increased uptake of 68 Ga-DOTA-NOC in BAT, it is unlikely that it can be used for the assessment of BAT.…”

“…reported increased 68 Ga‐DOTA‐NOC uptake in fat depots linked to BAT only in 1% of patients (Kagna et al . ). Considering the very low prevalence of increased uptake of 68 Ga‐DOTA‐NOC in BAT, it is unlikely that it can be used for the assessment of BAT.…”